Zev A. Wainberg

Zev Wainberg is a GI oncologist who has contributed to development of novel targeted therapies in gastric and gastroesophageal junction cancer including CLDN18.2 targeting. He led investigator participation in the SPOTLIGHT and GLOW trials establishing zolbetuximab plus chemotherapy as first-line therapy for CLDN18.2-positive, HER2-negative gastric cancer, representing a new targetable biomarker beyond HER2 in gastric cancer. Wainberg has contributed to development of FGFR2b inhibitors, fibroblast growth factor receptor targeted agents, and immunotherapy combinations in esophagogastric cancers, and leads a translational research program on gastric cancer biology.